Administer orally, preferably on an empty stomach (one hour before or two hours after meals) to minimize nausea or vomiting. Take with a full glass of water.

Bethanechol selectively stimulates muscarinic receptors, particularly M3 receptors in the bladder detrusor muscle, leading to increased bladder tone, contraction of the detrusor muscle, and relaxation of the trigone and external sphincter, thereby promoting micturition.

• •Hypersensitivity to bethanechol or any component of the formulation.
• •Mechanical obstruction of the gastrointestinal or urinary tract.
• •Hyperthyroidism, peptic ulcer, bronchial asthma, cardiac disease (e.g., severe bradycardia, AV conduction defects, hypotension, coronary artery disease), epilepsy, parkinsonism.
• •Recent myocardial infarction, conditions where increased gastrointestinal or urinary tract motility might be harmful (e.g., bladder neck obstruction, spastic gastrointestinal disturbances), peritonitis, acute inflammatory lesions of the gastrointestinal tract.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms of overdose include severe nausea, vomiting, abdominal cramps, diarrhea, salivation, sweating, flushing, bradycardia, hypotension, and circulatory collapse. Treatment involves discontinuation of the drug and administration of atropine sulfate (0.6 mg subcutaneous or intravenous) as an antidote. Supportive measures should be provided.

Pregnancy Category C. Use in pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether bethanechol is excreted in human milk; use with caution in nursing mothers.